- OncoMed Pharmaceuticals (OMED) starts a Phase 1b dose escalation trial for vantictumab (with paclitaxel) in patients with first-, second- and third-line, locally advanced or metastatic HER2 negative breast cancer.
- OMED intends to initiate three Phase 1 trials of vantictumab this year. (PR)
- The company is developing the drug with Bayer (BAYZF).
OncoMed Pharmaceuticals initiates breast cancer study with vantictumab
Oct 29 2013, 08:47 ET